Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

3 months ago talkbio0Tagged Approved, DTC Campaign, Empowerment, Myasthenia Gravis, Generalized, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, self-administration, Syringes, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

8 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.

Argenx’s Vyvgart Hytrulo Secures Second US Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

1 year ago talkbio0Tagged Approved, Argenx, Autoimmune Diseases, Peripheral Nervous System Diseases, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, Argenx, FDA Approval, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Disease, Peripheral Nervous System Disorder